<p>Long Non-Coding RNA SLC25A21-AS1 Promotes Multidrug Resistance in Nasopharyngeal Carcinoma by Regulating miR-324-3p/IL-6 Axis</p>

Abstract

Background: Nasopharyngeal carcinoma (NPC), one of the most common types of head and neck tumor, occurred in the epithelial lining of the nasopharynx and is mainly prevalent in Southeast Asia and Southern China. However, the molecular mechanisms of NPC multidrug resistance still remained largely unclear. Methods: The qRT-PCR assay was performed to examine SLC25A21-AS1, miR-324-3p and IL-6 expression in NPC tissues and cell. The CCK8 assay and colony formation assay were used to detect cell growth. In addition, CCK8 assay was performed to detect IC 50 values of different drugs in NPC cell. Results: In this study, we found that SLC25A21-AS1 expression was increased in NPC tissues and cell line, and knockdown of SLC25A21-AS1 inhibited cell growth and MDR in NPC cell. Moreover, SLC25A21-AS1 acted as a ceRNA for miR-324-3p and facilitates NPC cell growth and MDR by regulating the miR-324-3p/IL-6 axis. Conclusion: Our findings demonstrated the role of SLC25A21-AS1/miR-324-3p/IL-6 axis in cell growth and MDR in NPC, which might be a potential prognostic and diagnostic marker in NPC patients and provide new insight into the molecular mechanism of MDR in NPC chemotherapy.

Lipid metabolism–related lncRNA SLC25A21‐AS1 promotes the progression of oesophageal squamous cell carcinoma by regulating the NPM1/c‐Myc axis and SLC25A21 expression

“…In addition, a previous study showed that SLC25A21‐AS1 is associated with multidrug resistance 27 . The present study demonstrated that the rate of cisplatin‐induced apoptosis was significantly increased in SLC25A21‐AS1 ‐knockdown cells and decreased in SLC25A21‐AS1‐overexpressing cells (Figure 8F).…”

“…67,68 A previous study indicated that SLC25A21-AS1 is associated with multidrug resistance. 27 The present study demonstrated that SLC25A21-AS1 overexpression conferred resistance to cisplatin-induced apoptosis, whereas SLC25A21-AS1 knockdown enhanced chemosensitivity. Currently, antisense oligonucleotides, RNA interference (RNAi) technology, small molecule inhibitors, and CRISPR/Cas9 are therapeutic strategies targeting lncRNAs.…”

Analysis of ceRNA networks and identification of potential drug targets for drug-resistant leukemia cell K562/ADR

“…Therefore, these findings are of great significance to explore the pathogenesis and treatment of CML. Some literatures have shown that ceRNA network participates in the occurrence of MDR in cancers, including nasopharyngeal carcinoma (Wang et al, 2020) and AML (Yu et al, 2020). However, except for one paper (Zhang et al, 2019), there is no other report on ceRNA regulatory network and its role in MDR-CML.…”

Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Nasopharyngeal Carcinoma

“…In addition, high expression of SLC25A21-AS1 could target miR-324-3p and thus mediate IL-6, resulting in enhanced proliferation and multidrug resistance in NPC cells. 101 It has been reported that lnc C00346 targets miR-342-5p and reduces the sensitivity of nasopharyngeal carcinoma cells to cisplatin. 102 In addition, a variety of lncRNAs may be involved in the regulation of chemotherapy sensitivity in nasopharyngeal carcinoma ( Table 2 ).…”

“… 105 In addition, lnc SLC25A21-AS1 regulates IL-6 by targeting miR-324-3p, making nasopharyngeal carcinoma resistant to multiple chemotherapeutic agents. 101 Li et al revealed that lnc DLEU1 inhibits miR-381-3p, resulting in increased expression of BIRC6 and increased resistance of nasopharyngeal carcinoma to the chemotherapeutic agent cisplatin. 95 Lin et al demonstrated that silencing lncRNA HOXA11-AS can inhibit the c-Met/AKT/mTOR pathway by specifically upregulating miR-454-3p, thus promoting cell apoptosis and enhancing the sensitivity of cisplatin-resistant NPC cells to cisplatin.…”